GYKI 52466 dihydrochloride|cas:2319722-40-0|西域试剂

GYKI 52466 dihydrochloride,99.38%

产品编号：Bellancom-103234A| CAS NO：2319722-40-0| 分子式：C₁₇H₁₇Cl₂N₃O₂| 分子量：366.24

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-103234A	￥1215.00	杭州北京（现货）
Bellancom-103234A	￥1890.00	杭州北京（现货）
Bellancom-103234A	￥4050.00	杭州北京（现货）
Bellancom-103234A	￥6480.00	杭州北京（现货）
Bellancom-103234A	￥11250.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

GYKI 52466 dihydrochloride

产品介绍

GYKI 52466 dihydrochloride 是一种具有口服活性、高选择性和非竞争性的 AMPA/Kainate 受体拮抗剂，其 IC₅₀ 值分别为 7.5 和 11 μM。GYKI 52466 dihydrochloride 具有良好的血脑屏障通透性和抗惊厥作用，可用于帕金森病的研究。

生物活性

GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research.

体外研究

GYKI 52466 (0.3-100 μM) inhibits inward currents activated by AMPA and Kainate receptor in cultured rat hippocampal neurons.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

GYKI 52466 (intraperitoneal injection; 1.76-13.2 mg/kg; once) treatment provides potent anticonvulsant protection against sound-induced seizures in DBA/2 mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male and female DBA/2 mice tested for sound-induced seizure responses
Dosage:	1.76-13.2 mg/kg
Administration:	Intraperitoneal injection; 1.76-13.2 mg/kg; once
Result:	Observed Maximal anticonvulsant protection after the i.p. treatment (5-15 min ).

体内研究

GYKI 52466 (intraperitoneal injection; 1.76-13.2 mg/kg; once) treatment provides potent anticonvulsant protection against sound-induced seizures in DBA/2 mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male and female DBA/2 mice tested for sound-induced seizure responses
Dosage:	1.76-13.2 mg/kg
Administration:	Intraperitoneal injection; 1.76-13.2 mg/kg; once
Result:	Observed Maximal anticonvulsant protection after the i.p. treatment (5-15 min ).

性状

Solid

溶解性数据

In Vitro:

DMSO : 2.78 mg/mL (7.59 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7304 mL	13.6523 mL	27.3045 mL
5 mM	0.5461 mL	2.7304 mL	5.4609 mL
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

参考文献